Guardant Health to Share Data at ESMO 2024 Further Demonstrating Strong Performance of Its Precision Oncology Technology in Multiple Advanced Tumor Types
Guardant Health (Nasdaq: GH) announced its participation in the European Society for Medical Oncology Congress (ESMO) 2024 in Barcelona. The company will present data demonstrating the performance of its precision oncology technology across multiple advanced tumor types. Key highlights include:
1. Guardant Reveal™ minimal residual disease test data in locally advanced rectal cancer patients (NO-CUT trial).
2. Guardant360® findings for therapy selection in advanced breast cancer and other solid tumors.
3. Guardant Infinity™ platform results for response monitoring in advanced non-small cell lung cancer (NSCLC).
The presentations aim to showcase the value of Guardant's liquid biopsy technology in informing therapy selection and treatment management across various cancer stages.
Guardant Health (Nasdaq: GH) ha annunciato la sua partecipazione al Congresso della Società Europea di Oncologia Medica (ESMO) 2024 a Barcellona. L'azienda presenterà dati che dimostrano le performance della sua tecnologia di oncologia di precisione su molteplici tipi di tumori avanzati. I punti salienti includono:
1. Dati del test di malattia minima residua Guardant Reveal™ in pazienti con carcinoma rettale localmente avanzato (studio NO-CUT).
2. Risultati di Guardant360® per la selezione della terapia nel carcinoma mammario avanzato e in altri tumori solidi.
3. Risultati della piattaforma Guardant Infinity™ per il monitoraggio della risposta nel carcinoma polmonare non a piccole cellule avanzato (NSCLC).
Le presentazioni hanno lo scopo di dimostrare il valore della tecnologia di biopsia liquida di Guardant nel supportare la selezione della terapia e la gestione del trattamento in diverse fasi del cancro.
Guardant Health (Nasdaq: GH) anunció su participación en el Congreso de la Sociedad Europea de Oncología Médica (ESMO) 2024 en Barcelona. La empresa presentará datos que demuestran el rendimiento de su tecnología de oncología de precisión en múltiples tipos de tumores avanzados. Los aspectos destacados incluyen:
1. Datos de la prueba de enfermedad residual mínima Guardant Reveal™ en pacientes con cáncer rectal localmente avanzado (ensayo NO-CUT).
2. Hallazgos de Guardant360® para la selección de tratamiento en cáncer de mama avanzado y otros tumores sólidos.
3. Resultados de la plataforma Guardant Infinity™ para el monitoreo de respuesta en cáncer de pulmón no microcítico avanzado (NSCLC).
Las presentaciones tienen como objetivo mostrar el valor de la tecnología de biopsia líquida de Guardant en la selección de terapias y la gestión del tratamiento en las distintas etapas del cáncer.
가드란트 헬스(Nasdaq: GH)가 바르셀로나에서 열리는 2024년 유럽의료종양학회(ESMO)에 참가한다고 발표했습니다. 이 회사는 여러 가지 진행성 종양 유형에서 정밀 종양학 기술의 성과를 보여주는 데이터를 발표할 예정입니다. 주요 내용은 다음과 같습니다:
1. 국소 진행성 직장암 환자에서의 최소 잔여 질환 테스트 데이터인 Guardant Reveal™(NO-CUT 시험).
2. 진행성 유방암 및 기타 고형 종양에서의 치료 선택을 위한 Guardant360® 결과.
3. 진행성 비소세포폐암(NSCLC)에서의 반응 모니터링을 위한 Guardant Infinity™ 플랫폼 결과.
발표는 다양한 암 단계에서의 치료 선택과 치료 관리를 지원하는 가드란트의 액체 생체검사 기술의 가치를 강조하는 것을 목표로 하고 있습니다.
Guardant Health (Nasdaq: GH) a annoncé sa participation au Congrès de la Société Européenne d'Oncologie Médicale (ESMO) 2024 à Barcelone. L'entreprise présentera des données démontrant la performance de sa technologie d'oncologie de précision dans plusieurs types de tumeurs avancées. Les points clés incluent :
1. Données du test de maladie résiduelle minimale Guardant Reveal™ chez des patients atteints de cancer rectal localement avancé (essai NO-CUT).
2. Résultats de Guardant360® pour la sélection des thérapies dans le cancer du sein avancé et d'autres tumeurs solides.
3. Résultats de la plateforme Guardant Infinity™ pour le suivi de la réponse dans le cancer du poumon non à petites cellules avancé (NSCLC).
Les présentations visent à mettre en valeur la technologie de biopsie liquide de Guardant pour informer la sélection des thérapies et la gestion des traitements à différents stades du cancer.
Guardant Health (Nasdaq: GH) hat seine Teilnahme am Kongress der Europäischen Gesellschaft für Medizinische Onkologie (ESMO) 2024 in Barcelona angekündigt. Das Unternehmen wird Daten präsentieren, die die Leistung seiner präzisionsonkologischen Technologie bei mehreren fortgeschrittenen Tumorarten demonstrieren. Die wichtigsten Highlights sind:
1. Daten des minimalresidualen Krankheits-Tests Guardant Reveal™ bei Patienten mit lokal fortgeschrittenem Rektumkarzinom (NO-CUT-Studie).
2. Ergebnisse von Guardant360® zur Therapiuauswahl bei fortgeschrittenem Brustkrebs und anderen soliden Tumoren.
3. Ergebnisse der Guardant Infinity™-Plattform zur Reaktionsüberwachung bei fortgeschrittenem nicht-kleinzelligem Lungenkrebs (NSCLC).
Die Präsentationen zielen darauf ab, den Wert der Flüssigbiopsie-Technologie von Guardant zu demonstrieren, um die Therapiuauswahl und das Behandlungsmanagement in verschiedenen Krebsstadien zu unterstützen.
- Guardant Health will present data at ESMO 2024, demonstrating strong performance of its precision oncology technology
- The company's Guardant Reveal™ test data will be featured in a Presidential Symposium session
- Multiple studies showcasing Guardant's technology across various cancer types and stages
- None.
The upcoming ESMO 2024 presentations highlight Guardant Health's continued progress in precision oncology. The NO-CUT trial data on Guardant Reveal™ for minimal residual disease in rectal cancer patients is particularly noteworthy, being featured in a prestigious Presidential Symposium. This suggests potential clinical significance and could impact treatment protocols.
Other presentations on Guardant360® and Guardant Infinity™ across various cancer types demonstrate the broad applicability of their liquid biopsy technology. The focus on therapy selection and response monitoring in advanced cancers like NSCLC and breast cancer indicates Guardant's commitment to improving personalized treatment strategies. These advancements could lead to expanded market opportunities and potential revenue growth for Guardant Health in the precision oncology space.
While the ESMO presentations don't provide immediate financial figures, they represent significant R&D progress for Guardant Health. The company's presence across multiple cancer types and stages showcases a diversified product portfolio, which could mitigate risk and enhance long-term growth prospects.
Investor focus should be on how these clinical advancements translate to market adoption and revenue generation. The inclusion in a Presidential Symposium may boost credibility and potentially accelerate sales of the Guardant Reveal™ test. However, the real financial impact will depend on future commercialization success and reimbursement policies. Investors should monitor for subsequent announcements on partnerships, regulatory approvals, or payer coverage that could more directly influence the company's financial performance.
Data on the Guardant Reveal™ minimal residual disease test in locally advanced rectal cancer patients enrolled in the NO-CUT trial will be presented in a proffered paper session during Presidential Symposium III. Other presentations will include findings from studies evaluating Guardant360® for therapy selection in advanced breast cancer and other solid tumors, and the Guardant Infinity™ platform for response monitoring in advanced non-small cell lung cancer (NSCLC).
“Our latest data featured at ESMO further highlight the value of Guardant’s technology in precision oncology and the critical role liquid biopsy can play in informing therapy selection and treatment management across multiple tumor types,” said Craig Eagle, M.D., chief medical officer at Guardant Health. “We look forward to sharing how Guardant tests can contribute to improved outcomes across all stages of cancer care.”
Complete list of Guardant Health and collaborator presentations at ESMO 2024
Abstract |
Title (Hall 6, unless otherwise noted) |
Product |
Saturday, September 14 | 9:00 - 17:00 |
||
1295P |
EP0031 a next-generation selective RET inhibitor (SRI): Correlation of molecular and clinical responses in patients with RET alteration positive solid tumours naïve to or following prior SRI |
Guardant Infinity
|
Sunday, September 15 | 9:00 - 17:00 |
||
127P |
Clinical utility of circulating tumor DNA (ctDNA) next generation sequencing (NGS) to inform treatment decisions for patients (pts) with advanced solid tumors |
Guardant 360
|
Monday, September 16 | 9:00 - 17:00 |
||
418P |
Concordance of PI3K-AKT pathway alterations between tumor and ctDNA in metastatic breast cancer |
Guardant 360
|
419P |
Prevalence of gene rearrangement on ctDNA NGS and its targetability in patients with advanced breast cancer |
Guardant 360
|
Monday, September 16 | 17:04 – 17:16 |
||
509O |
Total neoadjuvant treatment (TNT) with non-operative management (NOM) for proficient mismatch repair locally advanced rectal cancer (pMMR LARC): first results of NO-CUT Trial
Proffered Paper Session: Presidential Symposium III: Eyes to the future, Barcelona Auditorium, Hall 2 |
Guardant Reveal
|
The full abstracts for Guardant Health and a list of all abstracts being presented at the ESMO Congress can be found on the ESMO website.
For information and updates from the conference, follow Guardant Health on LinkedIn, X (Twitter) and Facebook or visit Guardant on-site at booth #510.
About Guardant Health
Guardant Health is a leading precision oncology company focused on guarding wellness and giving every person more time free from cancer. Founded in 2012, Guardant is transforming patient care and accelerating new cancer therapies by providing critical insights into what drives disease through its advanced blood and tissue tests, real-world data and AI analytics. Guardant tests help improve outcomes across all stages of care, including screening to find cancer early, monitoring for recurrence in early-stage cancer, and treatment selection for patients with advanced cancer. For more information, visit guardanthealth.com and follow the company on LinkedIn, X (Twitter) and Facebook.
Forward-Looking Statements
This press release contains forward-looking statements within the meaning of federal securities laws, including statements regarding the potential utilities, values, benefits and advantages of Guardant Health’s liquid biopsy tests or assays, which involve risks and uncertainties that could cause the actual results to differ materially from the anticipated results and expectations expressed in these forward-looking statements. These statements are based on current expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors. These and additional risks and uncertainties that could affect Guardant Health’s financial and operating results and cause actual results to differ materially from those indicated by the forward-looking statements made in this press release include those discussed under the captions “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operation” and elsewhere in its Annual Report on Form 10-K for the year ended December 31, 2023, and in its other reports filed with or furnished to the Securities and Exchange Commission thereafter. The forward-looking statements in this press release are based on information available to Guardant Health as of the date hereof, and Guardant Health disclaims any obligation to update any forward-looking statements provided to reflect any change in its expectations or any change in events, conditions, or circumstances on which any such statement is based, except as required by law. These forward-looking statements should not be relied upon as representing Guardant Health’s views as of any date subsequent to the date of this press release.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240912788752/en/
Investor Contact:
Zarak Khurshid
investors@guardanthealth.com
Media Contact:
Mike Weist
press@guardanthealth.com
+1 317 371 0035
Source: Guardant Health, Inc.
FAQ
What data will Guardant Health (GH) present at ESMO 2024?
When and where will ESMO 2024 take place?
What is the significance of Guardant Health's (GH) presentations at ESMO 2024?
Which Guardant Health (GH) product will be featured in the Presidential Symposium at ESMO 2024?
